Загрузка...
Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type
INTRODUCTION: Factors affecting trastuzumab efficacy in advanced gastric cancer (GC) are largely unknown. Heterogeneity is a notable feature of HER2 in GC. Whether the heterogeneity influences trastuzumab efficacy is still unknown. RESULTS: The HER2(homogeneous) group and HER2(heterogeneous) group s...
Сохранить в:
| Опубликовано в: : | Oncotarget |
|---|---|
| Главные авторы: | , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Impact Journals LLC
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5464860/ https://ncbi.nlm.nih.gov/pubmed/28388541 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16567 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|